Seattle Genetics Inc

Most Recent

  • uploads///projections
    Company & Industry Overviews

    What’s Nektar Therapeutics’ Guidance for Fiscal 2018?

    For full fiscal 2018, the company expects to register R&D (research and development) expenses of $400 million to $425 million.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    What Does the Future Hold for Seattle Genetics?

    Seattle Genetics has surpassed all estimates for earnings per share in the past.

    By Mike Benson
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Ultragenyx Woos Investors with Good Returns in Mid-Cap Space

    Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Horizon Rose and Outperformed IBB’s Mid-Cap Stocks

    Horizon Pharma rose 5.4% on November 16, 2015. The stock rose due to the update at the shareholder meeting regarding the Depomed acquisition.

    By Peter Neil
  • uploads///Chart
    Earnings Report

    Seattle Genetics’ 1Q16 Earnings: What Are Analysts Expecting?

    Seattle Genetics is set to release its first-quarter 2016 earnings on April 28, 2016. Analysts estimate revenues of around $116 million for 1Q16.

    By Mike Benson
  • uploads///Graph Part
    Company & Industry Overviews

    XBI Moving Averages Are on the Rise

    For the week ended September 11, 2015, the SPDR S&P Biotechnology ETF (XBI) saw a big jump in the number of stocks trading above the 20-day moving average.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Seattle Genetics Leads XBI Mid-Cap Stocks

    Seattle Genetics (SGEN) rose 14.56% for the week ended September 11, 2015. The stock closed at $45.01 and moved back to 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI’s Mid Caps: Ionis Gives Update on Nusinersen Phase 2 Study

    The mid-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 1% on April 20, 2016. Within XBI, Ionis Pharmaceuticals’ stock closed at $43.62 on the day.

    By Peter Neil
  • uploads///syringe pill capsule morphine
    Earnings Report

    Seattle Genetics Posted Strong Q2 2018 Results, Stock Rose

    Seattle Genetics reported sales of $170.2 million in the second quarter, which represented 57.2% growth YoY (year-over-year).

    By Sarah Collins
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial

    On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.

    By Peter Neil
  • uploads///close up drugs medical medicine
    Company & Industry Overviews

    Wall Street Is Bullish on Nektar Stock despite Stock Price Slump

    Nektar is a development-stage biotechnology company that has a drug pipeline focused on the treatment of cancer, autoimmune diseases, and chronic pain.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    What’s behind Nektar Therapeutics’ ~38% Fall in June?

    On June 27, Nektar Therapeutics (NKTR) ended the trading day at a closing price of $46.25.

    By Sarah Collins
  • uploads///Alkermes
    Company & Industry Overviews

    How’s Alkermes Positioned Financially in September?

    In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017.

    By Daniel Collins
  • uploads///SGEN
    Company & Industry Overviews

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

    By Kenneth Smith
  • uploads///SGEN
    Company & Industry Overviews

    What Seattle Genetics’ Bottom-Line Trend Indicates

    In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    How’s Seattle Genetics Positioned?

    Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

    By Kenneth Smith
  • uploads///IONS
    Company & Industry Overviews

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

    By Mike Benson
  • uploads///SGEN
    Company & Industry Overviews

    Seattle Genetics: Impact of the Cascadian Acquisition

    Seattle Genetics acquired clinical-stage biopharmaceutical company Cascadian in March for $614.1 million at $10.0 per share.

    By Kenneth Smith
  • uploads///SGEN RD
    Company & Industry Overviews

    Exploring Seattle Genetics’ Operational Performance

    Seattle Genetics (SGEN) incurred a cost of sales of $13.16 million in the second quarter—compared to $8.06 million in the second quarter of 2017.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    What’s Driving Seattle Genetics Stock in 2018?

    Seattle Genetics generated total revenues of $170.17 million in the second quarter—compared to $108.22 million in the same period in 2017.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates

    Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.

    By Mike Benson
  • uploads///oncology pipeline
    Earnings Report

    Seattle Genetics Increased Its Fiscal 2018 Outlook

    During the second-quarter earnings release, Seattle Genetics provided an increased guidance range for its fiscal collaboration sales.

    By Sarah Collins
  • uploads///blood _
    Company & Industry Overviews

    Why Advaxis Stock Is Soaring Today

    Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.

    By Daniel Collins
  • uploads///lab _
    Company & Industry Overviews

    How Analysts Are Rating Puma Biotechnology in July

    On July 5, Puma Biotechnology (PBYI) stock closed at $58.75, which represents a 25% growth from its 52-week low of $47 on June 7.

    By Daniel Collins
  • uploads///Keytruda revenues
    Company & Industry Overviews

    Merck’s Keytruda Receives a New Approval

    In June, the FDA approved Merck & Company’s Keytruda for the treatment of individuals with refractory primary mediastinal large B-cell lymphoma.

    By Daniel Collins
  • uploads///tapimmune
    Company & Industry Overviews

    TapImmune Stock: Why It Spiked 84% Last Week

    TapImmune (TPIV) stock saw an ~84.1% hike during the week of June 1–8. On June 8, it closed at $9.

    By Daniel Collins
  • uploads///cells _
    Company & Industry Overviews

    CRISPR Stock Has Seen Soild Growth in the Last 12 Months

    CRISPR Therapeutics has risen 24% between May 11 and May 17.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Key Updates on Akcea Therapeutics’ Volanesorsen

    Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis’s Key Revenue Drivers in 4Q17

    Ionis Pharmaceuticals (IONS) reported 7.5% growth in revenues to $172.3 million during 4Q17 as compared to revenues of $160.3 million during 4Q16.

    By Mike Benson
  • uploads///Kymriah Juliet
    Company & Industry Overviews

    Key Updates on Novartis’s Kymriah

    In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

    By Daniel Collins
  • uploads///Kymriah
    Company & Industry Overviews

    How Is Novartis’s Kymriah Positioned for 2018?

    FDA and EC approvals for label expansion are expected to further boost Kymriah’s sales growth.

    By Daniel Collins
  • uploads///Opdivo
    Company & Industry Overviews

    Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb

    In 1Q17, 2Q17, and 3Q17, Opdivo reported revenues of $1.1 billion, $1.2 billion, and $1.3 billion, respectively.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in November 2017

    In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.

    By Daniel Collins
  • uploads///Analysts reco
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in August 2017

    In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in June 2017

    Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”

    By Daniel Collins
  • uploads///Chart  Adcetris Opdivo
    Company & Industry Overviews

    Adcetris-Opdivo Combination for Classical Hodgkin Lymphoma

    Bristol-Myers Squibb and Seattle Genetics are evaluating the Adcetris-Opdivo combination to treat patients with relapsed classical Hodgkin Lymphoma.

    By Mike Benson
  • uploads///Chart  Adcetris and Opdivo
    Company & Industry Overviews

    Updates on the Adcetris and Opdivo Combination

    Bristol-Myers Squibb and Seattle Genetics are evaluating a combination of Opdivo with Adcetris to treat refractory or relapsed classical Hodgkin Lymphoma.

    By Mike Benson
  • uploads///Chart  Checkmate
    Company & Industry Overviews

    Data from the Checkmate-205 Study Evaluating Opdivo

    Follow-up data were released from the Checkmate-205 study. It evaluated long-term effects of PD-1 inhibitors in patients with classical Hodgkin Lymphoma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Is Mylan’s Generics Segment Doing?

    Mylan’s (MYL) 3Q16 revenues were mainly driven by a 17.0% rise in sales for its Generics segment. The segment reported $2.6 billion in sales in 3Q16.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Holdings: How Are Their Moving Averages Trending?

    The iShares Nasdaq Biotechnology ETF (IBB) has 189 stocks in its portfolio. As of June 6, 2016, 87% of IBB’s stocks were trading above their 20-day moving averages.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Ionis’s Metabolic Segment: Phase I and Phase II Studies

    Ionis Pharmaceuticals (IONS) is developing drugs for the treatment of various types of metabolic disorders, including diabetes, obesity, and non-alcoholic steatohepatitis.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Seattle Genetics’ Valuation: How Does It Compare?

    We believe that the enterprise-value-to-revenue multiple is the best measure for valuing Seattle Genetics (SGEN) and similar companies.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Can We Expect from Seattle Genetics’s Adcetris in 1Q16?

    Adcetris is an anti-CD30 monoclonal antibody that targets CD30, which is a marker for lymphoma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Ionis Pharmaceuticals Doing with IONIS-TTR?

    In March 2010, Ionis entered into a preferred partner alliance with GlaxoSmithKline (GSK) for the development and commercialization of IONIS-TTR.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Existing Chemotherapy Drugs for Lymphoma

    Opdivo is under phase II study for the use in the treatment of relapsed or refractory classical Hodgkin’s lymphoma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    EMA Validates Opdivo’s Application for Additional Indications

    Opdivo is an oncology drug from Bristol-Myers Squibb that is already approved by the FDA and EMA for the treatment of patients with melanoma. On March 30, EMA validated the type-II variation application for extending the current indications for Opdivo.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI on a Downward Slope, but How Steep?

    On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.

    By Peter Neil
  • uploads///Pomalyst and Abraxane Revenue Part
    Earnings Report

    Pomalyst and Abraxane Revenues Are Critical for Celgene

    Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    ALNY and JAZZ Hindered the Top 10 Mid-Cap Stocks on October 21

    The top ten mid-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the IBB and the SPDR S&P 500 ETF (SPY) as of October 21, with a return of -0.2% compared to IBB’s -0.5% and SPY’s -0.6%.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Medivation and Bluebird Led IBB’s Mid-Cap Stocks Last Week

    Medivation and Bluebird led IBB’s mid-cap stocks for the week ended September 18, 2015.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Valuation Multiples for Biotechnology ETFs in Week Ended July 24

    Within the iShares Nasdaq Biotechnology ETF (IBB), the biotechnology sector has a P/B ratio of 11.54x. The P/B ratio for the pharmaceuticals sector is 11.32x.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.